guselkumab

Home
Ligands
guselkumab

GtoPdb Ligand ID: 7998

Synonyms: CNTO-1959 | Tremfya®

guselkumab is an approved drug (EMA & FDA (2017))

Comment: Guselkumab is a monoclonal antibody directed against interleukin-23A (IL23A). It is being investigated as a treatment for plaque psoriasis.
Annotated peptide sequences for this antibody are available from its IMGT/mAb-DB record.

References
1. Benson J, Carton J, Mark Cunningham M, Orlovsky YI, Rauchenberger R, Sweet R. (2011) Human anti-IL-23 antibodies, compositions, methods and uses. Patent number: US7935344. Assignee: Centocor Ortho Biotech Inc.. Priority date: 29/12/2005. Publication date: 01/05/2011.
2. Chan JR, Blumenschein W, Murphy E, Diveu C, Wiekowski M, Abbondanzo S, Lucian L, Geissler R, Brodie S, Kimball AB et al.. (2006) IL-23 stimulates epidermal hyperplasia via TNF and IL-20R2-dependent mechanisms with implications for psoriasis pathogenesis. J Exp Med, 203 (12): 2577-87. [PMID:17074928]
3. Miossec P, Kolls JK. (2012) Targeting IL-17 and TH17 cells in chronic inflammation. Nat Rev Drug Discov, 11 (10): 763-76. [PMID:23023676]
4. Murphy CA, Langrish CL, Chen Y, Blumenschein W, McClanahan T, Kastelein RA, Sedgwick JD, Cua DJ. (2003) Divergent pro- and antiinflammatory roles for IL-23 and IL-12 in joint autoimmune inflammation. J Exp Med, 198 (12): 1951-7. [PMID:14662908]
5. Sofen H, Smith S, Matheson RT, Leonardi CL, Calderon C, Brodmerkel C, Li K, Campbell K, Marciniak Jr SJ, Wasfi Y et al.. (2014) Guselkumab (an IL-23-specific mAb) demonstrates clinical and molecular response in patients with moderate-to-severe psoriasis. J Allergy Clin Immunol, 133 (4): 1032-40. [PMID:24679469]

References

1. Benson J, Carton J, Mark Cunningham M, Orlovsky YI, Rauchenberger R, Sweet R. (2011)
Human anti-IL-23 antibodies, compositions, methods and uses.
Patent number: US7935344. Assignee: Centocor Ortho Biotech Inc.. Priority date: 29/12/2005. Publication date: 01/05/2011.

2. Chan JR, Blumenschein W, Murphy E, Diveu C, Wiekowski M, Abbondanzo S, Lucian L, Geissler R, Brodie S, Kimball AB et al.. (2006)
IL-23 stimulates epidermal hyperplasia via TNF and IL-20R2-dependent mechanisms with implications for psoriasis pathogenesis.
J Exp Med, 203 (12): 2577-87. [PMID:17074928]

3. Miossec P, Kolls JK. (2012)
Targeting IL-17 and TH17 cells in chronic inflammation.
Nat Rev Drug Discov, 11 (10): 763-76. [PMID:23023676]

4. Murphy CA, Langrish CL, Chen Y, Blumenschein W, McClanahan T, Kastelein RA, Sedgwick JD, Cua DJ. (2003)
Divergent pro- and antiinflammatory roles for IL-23 and IL-12 in joint autoimmune inflammation.
J Exp Med, 198 (12): 1951-7. [PMID:14662908]

5. Sofen H, Smith S, Matheson RT, Leonardi CL, Calderon C, Brodmerkel C, Li K, Campbell K, Marciniak Jr SJ, Wasfi Y et al.. (2014)
Guselkumab (an IL-23-specific mAb) demonstrates clinical and molecular response in patients with moderate-to-severe psoriasis.
J Allergy Clin Immunol, 133 (4): 1032-40. [PMID:24679469]